Mid-regional pro-atrial natriuretic peptide (pro-ANP) for the identification of patients with atrial fibrillation with an onset of less than 48 hours ago
View Patent ↗The invention relates to a method for the determination of the time from onset of atrial fibrillation to presentation in a patient comprising the steps of: providing a sample of a bodily fluid of said patient, determining the level of proANP (SEQ ID NO: 1) or fragments thereof in said sample, correlating the level of proANP or fragments thereof to the time from the onset of atrial fibrillation to presentation of said patient, wherein said fragments have a length of at least 6 amino acid residues.
1. A method for the determination of the time from onset of atrial fibrillation to presentation of a patient comprising the steps of:
(i) providing a sample of a bodily fluid of said patient,
(ii) determining the level of proANP fragment MR-proANP (SEQ ID No: 4) in said sample,
(iii) correlating the level of proANP fragment MR-proANP (SEQ ID No: 4) to the time from the onset of atrial fibrillation to presentation of said patient, and
(iv) determining whether the time from the onset of atrial fibrillation to presentation of the patient is at or above a time cut-off value or below said time cut-off value,
wherein said time cut-off value is chosen from 48 hours and 24 hours.
2. The method according to claim 1 , wherein the time cut-off value is 48 hours.
3. The method according to claim 1 , wherein the time cut-off value is 24 hours.
4. The method according to claim 1 , wherein said sample is selected from blood, serum, plasma, cerebrospinal fluid, urine or saliva.
5. The method according to claim 1 , wherein the level of proANP or fragments thereof is determined using at least one antibody directed against an amino acid sequence corresponding to the proANP fragment MR-proANP (SEQ ID NO: 4).
6. The method according to claim 1 , wherein, when the time from the onset of atrial fibrillation to presentation of said patient is determined to be below said time cut-off value, this is taken as an indicator that the patient should be applied to immediate cardioversion.
7. The method according to claim 1 , wherein, when the time from the onset of atrial fibrillation to presentation of said patient is determined to be at or above said time cut-off value, this is taken as an indicator that the patient should be treated with anticoagulants and/or should undergo transesophageal echocardiogram (TEE) prior to cardioversion.
8. The method according to claim 6 , wherein cardioversion is electrical and/or pharmacological cardioversion.
9. The method according to claim 1 , wherein the time from the onset of atrial fibrillation to presentation of the patient is determined to be below said time cut-off value when said determined level of proANP fragment MR-proANP (SEQ ID No: 4) is lower than a predetermined threshold level.
10. The method according to claim 9 , wherein the predetermined threshold level is between 100 and 350 pmol/L.
11. The method according to claim 1 , wherein at least one biomarker is determined in addition to proANP fragment MR-proANP (SEQ ID No: 4), wherein the at least one biomarker is chosen from a biomarker related to a cardiovascular disease, a biomarker related to atrial fibrillation, pro-BNP and fragments thereof, NT-proBNP, BNP, and combinations thereof.
12. The method according to claim 1 , wherein additionally at least one clinical parameter is determined which may influence the level of proANP or fragments thereof in said patient.
13. The method according to claim 12 , wherein the clinical parameter is chosen from age, gender, comorbidity and body mass index (BMI).
14. The method according to claim 9 , wherein the predetermined threshold level is between 100 pmol/L and 250 pmol/L.
15. The method according to claim 9 , wherein the predetermined threshold level is between 100 pmol/L and 190 pmol/L.
16. The method according to claim 9 , wherein the predetermined threshold level is between 100 pmol/L and 160 pmol/L.